Merck KGaA (FRA:MRK) Given a €114.00 Price Target at Sanford C. Bernstein
Sanford C. Bernstein set a €114.00 ($132.56) price target on Merck KGaA (FRA:MRK) in a report released on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other equities analysts have also recently weighed in on MRK. DZ Bank reissued a buy rating on shares of Merck KGaA in a research report on Wednesday, August 14th. Warburg Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, July 30th. Credit Suisse Group set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a buy rating in a research report on Friday, September 6th. Bank of America set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a neutral rating in a research report on Friday, September 13th. Finally, Barclays set a €85.00 ($98.84) price target on shares of Merck KGaA and gave the stock a sell rating in a research report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and five have given a buy rating to the stock. The stock has an average rating of Hold and an average target price of €101.88 ($118.47).
FRA:MRK traded up €1.85 ($2.15) on Thursday, reaching €108.00 ($125.58). The stock had a trading volume of 770,765 shares. The company has a 50-day moving average of €105.44 and a 200 day moving average of €96.92. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: How liquidity affects the bid-ask spread
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.